NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
     
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel Employers
 Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

BIOTECH WORK PORTAL
Career Definitions
Labor Market Reports
Education & Training
Regions

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

ArQule, Inc. 

19 Presidential Way

Woburn  Massachusetts  01801  U.S.A.
Phone: 781-994-0300 Fax: 781-376-6019


SEARCH JOBS

View Clinical Trials from BioPharm Insight

ArQule, Inc. is engaged in the research, development, and commercialization of broadly effective, small molecule cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics. ArQule's lead clinical-stage products are based on its Activated Checkpoint TherapySM platform, designed to restore and activate cellular checkpoints, and on its Cancer Survival Pathway platform, designed to block the c-Met receptor tyrosine kinase. Pre-clinical programs are focused on multiple additional biological targets implicated in the growth of cancer. The targets, mechanisms of action and chemistry related to compounds generated from ArQule’s oncology programs differ, offering the potential for multiple therapeutic opportunities. Throughout these programs, the Company's molecular biology capabilities are enhanced by its strengths in chemistry technology.

 Key Statistics


Email: Info@arqule.com
Ownership:
Web Site: ArQule, Inc.
Employees: 130
Symbol: ARQL
 



Industry
Biotechnology

Segment
Drug Discovery





 Company News
Drug Discovery Capabilities of ArQule, Inc. (ARQL) Kinase Inhibitor Platform Presented at AACR-NCI-EORTC Conference 11/16/2009 2:56:05 PM    More...
ArQule, Inc. (ARQL) to Present at Lazard Capital Markets Sixth Annual Healthcare Conference on November 17, 2009 11/10/2009 9:22:28 AM    More...
ArQule, Inc. (ARQL) Announces Third Quarter Fiscal 2009 Results 11/5/2009 9:40:30 AM    More...
ArQule, Inc. (ARQL) to Report Third Quarter 2009 Financial Results on Thursday, November 5, 2009 10/29/2009 9:45:21 AM    More...
ArQule, Inc. (ARQL) to Present at Oppenheimer 20th Annual Healthcare Conference on November 3, 2009 10/28/2009 9:57:22 AM    More...
ArQule, Inc. (ARQL) to Introduce Novel FGFR Inhibitor Program Discovered Through Its Proprietary Kinase Inhibitor Platform at ArQule, Inc. (ARQL)-American Association for Cancer Research-EORTC Conference 10/15/2009 8:03:39 AM    More...
ArQule, Inc. (ARQL): European Medicines Evaluation Agency Grants Orphan Drug Designation to ARQ 197 for Treatment of Soft Tissue Sarcoma 10/14/2009 9:20:40 AM    More...
ArQule, Inc. (ARQL) Provides Clinical Update on ARQ 197 10/5/2009 9:36:07 AM    More...
ArQule, Inc. (ARQL) to Present at UBS Global Life Sciences Conference on September 21, 2009 9/14/2009 10:29:06 AM    More...
ArQule, Inc. (ARQL) to Present at Rodman & Renshaw Annual Global Investment Conference on September 9, 2009 9/2/2009 9:19:22 AM    More...
12345678910...